FDA grants first clearance for patient-facing LLM diabetes app, marking historic step for AI in medical software
UpDoc's diabetes management app received FDA clearance, the first for software that uses patient-facing large language models.
The app is designed to help patients follow treatment plans set by their doctors, providing insulin dosing recommendations based on glucose inputs, similar to existing drug dose calculators.
UpDoc's CEO declined to confirm whether the LLM makes clinical decisions, sparking debate about the role of generative AI as an interface versus a decision-maker.
The clearance, announced after a December review, places the product in a regulated category and could influence how health systems manage chronic conditions outside the clinic.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?”
read at STAT ↗
comments(0)
5-min edit window · permanent after that